Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunotherapy |
| gptkbp:administeredBy |
gptkb:physician
self-injection |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1996 |
| gptkbp:ATCCode |
L03AB07
|
| gptkbp:brand |
gptkb:Rebif
gptkb:Avonex |
| gptkbp:CASNumber |
220581-49-7
|
| gptkbp:category |
gptkb:insulin
disease-modifying therapy |
| gptkbp:contraindication |
hypersensitivity to interferon beta
|
| gptkbp:effect |
reduces relapse rate in MS
slows progression of disability in MS |
| gptkbp:eliminatedIn |
renal
|
| gptkbp:form |
solution for injection
|
| gptkbp:halfLife |
10 hours (approximate)
|
| https://www.w3.org/2000/01/rdf-schema#label |
Interferon beta-1a
|
| gptkbp:immunogenicity |
may induce neutralizing antibodies
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
modulates immune response
|
| gptkbp:metabolism |
proteolytic degradation
|
| gptkbp:molecularWeight |
approximately 22.5 kDa
|
| gptkbp:monitors |
liver function tests
thyroid function blood cell counts |
| gptkbp:notRecommendedFor |
primary progressive multiple sclerosis
|
| gptkbp:origin |
human interferon beta gene
|
| gptkbp:pharmacokinetics |
bioavailability 50-60% (subcutaneous)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
relapsing-remitting multiple sclerosis
|
| gptkbp:producedBy |
recombinant DNA technology
|
| gptkbp:product |
gptkb:protein
|
| gptkbp:riskFactor |
gptkb:anemia
thrombocytopenia liver toxicity leukopenia thyroid dysfunction |
| gptkbp:routeOfAdministration |
intramuscular injection
subcutaneous injection |
| gptkbp:sideEffect |
gptkb:depression
injection site reaction flu-like symptoms liver enzyme elevation |
| gptkbp:storage |
refrigerated
|
| gptkbp:target |
gptkb:interferon_receptors
|
| gptkbp:UNII |
P18A0J2Y9T
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Biogen_Inc.
|
| gptkbp:bfsLayer |
7
|